Curated News
By: NewsRamp Editorial Staff
August 10, 2026
Tonix Pharmaceuticals Surges with TONMYA Sales and Pipeline Progress
TLDR
- Tonix Pharmaceuticals' TONMYA sales surged to $11M in Q2 2026, with prescriptions up 100% sequentially, positioning the company for market dominance.
- Tonix's TONMYA revenue growth stems from 12,592 total prescriptions, including a 207% rise in refills, driven by expanding insurance coverage to 136 million lives.
- Tonix's TONMYA offers new hope for fibromyalgia patients, with expanded coverage improving access to the first new treatment in over 15 years.
- Tonix's fibromyalgia drug TONMYA saw prescriptions double in Q2, with a 207% jump in refills, signaling strong patient adherence and satisfaction.
Impact - Why it Matters
This news matters because it highlights a significant commercial milestone for Tonix Pharmaceuticals, demonstrating the market acceptance of TONMYA as a new treatment option for fibromyalgia, a condition affecting millions. The robust revenue growth and rapid prescription uptake indicate a strong product launch, which could lead to sustained revenue streams and potential profitability for the company. Additionally, the progress in clinical trials for major depressive disorder and Lyme disease prevention underscores the company's commitment to addressing high unmet medical needs, which could bring innovative therapies to patients in the future. For investors, the strong financial position and pipeline developments suggest potential for long-term growth.
Summary
Tonix Pharmaceuticals (NASDAQ: TNXP) has reported a strong second-quarter 2026, with net product revenue reaching approximately $13.5 million, a significant jump from $2 million in the same period last year. This growth was primarily fueled by $11 million in net sales of TONMYA, its newly approved treatment for fibromyalgia. The drug saw a 100% sequential increase in total prescriptions to 12,592, with new patient prescriptions up 36% and refills soaring 207%. TONMYA's market access has expanded to cover around 136 million lives across commercial, managed Medicare, and Medicaid channels, with expectations to reach approximately 145 million lives once a managed Medicare agreement takes effect on January 1, 2027.
Beyond its commercial success, Tonix continues to advance its clinical pipeline. The company has enrolled the first patient in the potentially pivotal Phase 2 HORIZON study of TNX-102 SL for major depressive disorder, and it is preparing to initiate an adaptive Phase 2 field study of TNX-4800 for Lyme disease prevention in the first quarter of 2027, pending FDA review. Tonix ended the quarter with about $176.2 million in cash and cash equivalents, which, along with third-quarter equity proceeds, is expected to fund operations into early second-quarter 2027. For more details, visit the full press release at https://nnw.fm/6Yytj.
Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments. TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg) is the first new fibromyalgia treatment in over 15 years. The company's CNS portfolio also includes acute migraine products Zembrace SymTouch and Tosymra, as well as TNX-2900 for Prader-Willi syndrome. In immunology, Tonix is developing TNX-4800 for Lyme disease prophylaxis and TNX-1500 for kidney transplant rejection prevention. The company's newsroom is available at https://nnw.fm/TNXP for the latest updates.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Tonix Pharmaceuticals Surges with TONMYA Sales and Pipeline Progress
